Fig. 9
The anti-tumor efficacy of different formulations on B16F10 tumor-bearing mice. C57BL/6 mice were injected subcutaneously with B16F10 cells (5 × 105), and tumor development and survival were monitored for 40 days. Nanoliposomal peptides were found to significantly improve tumor development and survival outcomes in comparison to mice receiving buffer and naïve liposome. The experimental schedule is shown in A, and the tumor volume (mm3) of each mouse in each vaccinated and control group is shown in B. The average tumor growth rate in all treated groups is shown in C, while survival is displayed in D, and the average body weight of all mice is shown in E. The data are expressed as mean ± SEM (n = 7). Statistically significant differences are displayed as follows: ns, * P > 0.05, ** P < 0.05, *** P < 0.01, **** P < 0.0001